Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
In addition to supporting GLP-1 activity, published data demonstrate the effects on leptin, adiponectin, insulin sensitivity and key digestive enzymes
Certain formulations have separate FDA approvals for chronic weight management (Wegovy, Saxenda, Zepbound), with higher-dose semaglutide and tirzepatide capable of producing 1015% weight reduction, while other GLP-1 agents typically yield more modest weight loss
Potential interactions with insulin and other antidiabetic agents should be considered
If you notice persistent or concerning changes in your urine whilst taking Saxenda, it is advisable to discuss these observations with your GP or prescribing clinician to rule out other potential causes
